Should I buy or sell PTC Therapeutics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 5 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" PTCT shares. View PTCT analyst ratings or view top-rated stocks .

What is PTC Therapeutics' stock price target for 2024?

13 brokers have issued 1-year price objectives for PTC Therapeutics' shares. Their PTCT share price targets range from $17.00 to $55.00. On average, they predict the company's stock price to reach $33.53 in the next year. This suggests a possible upside of 29.4% from the stock's current price. View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts .

How have PTCT shares performed in 2024?

PTC Therapeutics' stock was trading at $27.56 on January 1st, 2024. Since then, PTCT stock has decreased by 6.0% and is now trading at $25.92. View the best growth stocks for 2024 here .

When is PTC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our PTCT earnings forecast .

How can I listen to PTC Therapeutics' earnings call?

PTC Therapeutics will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were PTC Therapeutics' earnings last quarter?

PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.29 by $0.53. The biopharmaceutical company had revenue of $307.06 million for the quarter, compared to the consensus estimate of $315.90 million.

What ETFs hold PTC Therapeutics' stock?

ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Morningstar US Small Growth (MSGR) , iShares Neuroscience and Healthcare ETF (IBRN) , Invesco Biotechnology & Genome ETF (PBE) , Virtus LifeSci Biotech Products ETF (BBP) , Franklin Genomic Advancements ETF (HELX) , Harbor Corporate Culture Small Cap ETF (HAPS) , SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC) .

What guidance has PTC Therapeutics issued on next quarter's earnings?

PTC Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $600.0 million-$680.0 million, compared to the consensus revenue estimate of $612.3 million.

What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?

24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com . Stuart W. Peltz has an approval rating of 77% among the company's employees.

What other stocks do shareholders of PTC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU) , Sarepta Therapeutics (SRPT) , Alibaba Group (BABA) , GW Pharmaceuticals (GWPH) , Bausch Health Companies (BHC) , NVIDIA (NVDA) , Cisco Systems (CSCO) , Regulus Therapeutics (RGLS) , Aduro Biotech (ADRO) and Gilead Sciences (GILD) .

Who are PTC Therapeutics' major shareholders?

PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson , Christine Marie Utter , David P Southwell, Dawn Svoronos , Emily Luisa Hill , Emma Reeve, Eric Pauwels , Lee Scott Golden, Mark Elliott Boulding , Matthew B Klein , Michael Schmertzler, Neil Gregory Almstead , Pierre Gravier, Stephanie Okey and Stuart Walter Peltz . View institutional ownership trends .

How do I buy shares of PTC Therapeutics?

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Lowest-Rated StocksLowest-Rated

NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Price, News & Analysis

→ Your eBook: Mastering Earnings Announcements Trading (From StockEarnings) (Ad)

Free PTCT Stock Alerts

$25.34

-0.34 (-1.32%)

(As of 02:46 PM ET)

Compare

Today's Range: $25.17
▼
$26.32
50-Day Range: $24.15
▼
$31.95
52-Week Range: $17.53
▼
$59.84

Volume: 388,997 shs
Average Volume: 935,817 shs
Market Capitalization: $1.94 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.53

Get PTC Therapeutics alerts:

PTC Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.85 Rating Score
Upside/Downside: 29.4% Upside
$33.53 Price Target
Short Interest: Bearish
13.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.38
Upright™ Environmental Score
News Sentiment: 0.50
Based on 5 Articles This Week
Insider Trading: Selling Shares
$335,865 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.95) to ($5.36) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.24 out of 5 stars

Medical Sector

325th out of 930 stocks

Pharmaceutical Preparations Industry

146th out of 429 stocks

2.9

Analyst's Opinion

Consensus Rating
PTC Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.85, and is based on 3 buy ratings, 5 hold ratings, and 5 sell ratings.
Amount of Analyst Coverage
PTC Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
13.39% of the outstanding shares of PTC Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
PTC Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
Change versus previous month
Short interest in PTC Therapeutics has recently decreased by 5.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
PTC Therapeutics does not currently pay a dividend.
Dividend Growth
PTC Therapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
PTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.
Environmental Sustainability
The Environmental Impact score for PTC Therapeutics is -1.38.

1.9

News and Social Media Coverage

News Sentiment
PTC Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for PTC Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 1 people have searched for PTCT on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $335,865.00 in company stock.
Percentage Held by Insiders
Only 5.30% of the stock of PTC Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for PTC Therapeutics are expected to grow in the coming year, from ($5.95) to ($5.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PTC Therapeutics is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PTC Therapeutics is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad StockEarnings

Your eBook: Mastering Earnings Announcements Trading

Trading around earnings announcements (Pre-Earnings, Into-Earnings, and Post-Earnings) provides a unique trading opportunity. That is because trading around earnings announcements presents short-term trading opportunities (these are great because they don’t tie your money up for very long).

Click Here to Claim Your FREE The Ultimate Strategy Guide To Trade Earnings E-Book .

About PTC Therapeutics Stock (NASDAQ:PTCT)

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PTCT Stock News Headlines

April 5, 2024 | insidertrades.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $14,922.62 in Stock

April 14, 2024 | americanbankingnews.com

PTC Therapeutics (NASDAQ:PTCT) Stock Rating Reaffirmed by Cantor Fitzgerald

April 16, 2024 | StockEarnings (Ad)

Your eBook: Mastering Earnings Announcements Trading

April 11, 2024 | finance.yahoo.com

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

April 11, 2024 | prnewswire.com

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results

April 7, 2024 | americanbankingnews.com

Insider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $14,922.62 in Stock

April 1, 2024 | msn.com

Solid Biosciences gets FDA rare pediatric disease status for DMD therapy

March 28, 2024 | finance.yahoo.com

PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA

April 16, 2024 | StockEarnings (Ad)

Your eBook: Mastering Earnings Announcements Trading

March 19, 2024 | markets.businessinsider.com

Buy Rating for PTC Therapeutics Bolstered by Positive Regulatory Prospects and Gene Therapy Advances

March 19, 2024 | markets.businessinsider.com

PTC Therapeutics Gains After Announcement Of Key Regulatory Updates

March 19, 2024 | finanznachrichten.de

PTC Therapeutics, Inc.: PTC Therapeutics Provides Key Regulatory Updates

March 19, 2024 | markets.businessinsider.com

PTC Therapeutics Submits BLA To FDA For Upstaza - Quick Facts

March 19, 2024 | finance.yahoo.com

PTC Therapeutics Provides Key Regulatory Updates

March 7, 2024 | markets.businessinsider.com

PTC Therapeutics: Navigating Challenges and Pursuing Growth Amidst Regulatory Hurdles

March 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for PTC Therapeutics Amid Promising Regulatory Progress and Market Opportunity

March 2, 2024 | finance.yahoo.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

PTC Therapeutics Full Year 2023 Earnings: EPS Misses Expectations

March 1, 2024 | markets.businessinsider.com

PTC Therapeutics: Hold Rating Amidst Revenue Downturn and Regulatory Hurdles

February 29, 2024 | finance.yahoo.com

PTC Therapeutics Inc (PTCT) Reports Robust Revenue Growth and Advances in Pipeline

February 29, 2024 | prnewswire.com

PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 28, 2024 | msn.com

PTC Therapeutics Q4 2023 Earnings Preview

February 28, 2024 | investing.com

PTC Therapeutics Inc (PTCT)

February 27, 2024 | prnewswire.com

PTC Therapeutics to Participate at Upcoming Investor Conferences

February 22, 2024 | finance.yahoo.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 18, 2024 | finance.yahoo.com

PTCT Jun 2024 10.000 put

February 18, 2024 | finance.yahoo.com

PTCT Mar 2024 19.000 put

See More Headlines

Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/16/2024
Next Earnings (Confirmed): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PTCT
CUSIP: N/A
CIK: 1070081
Web: www.ptcbio.com
Phone: (908) 222-7000
Fax: 908-222-7231
Employees: 988
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.53
High Stock Price Target: $55.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +32.9%
Consensus Rating: Reduce
Rating Score (0-4): 1.85
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-626,600,000.00
Net Margins: -66.82%
Pretax Margin: -74.23%
Return on Equity: N/A
Return on Assets: -32.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.02
Quick Ratio: 1.97

Sales & Book Value

Annual Sales: $937.82 million
Price / Sales: 2.06
Cash Flow: $2.31 per share
Price / Cash Flow: 10.91
Book Value: ($10.85) per share
Price / Book: -2.33

Miscellaneous

Outstanding Shares: 76,610,000
Free Float: 72,548,000
Market Cap: $1.93 billion
Optionable: Optionable
Beta: 0.67

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Matthew B. Klein F.A.C.S. (Age 52)
M.D., M.S., CEO & Director
Comp: $995.4k
Dr. Stuart W. Peltz Ph.D. (Age 64)
Co-Founder, Senior Consultant & Member of Scientific Advisory Board
Comp: $1.54M
Dr. Allan Steven Jacobson Ph.D. (Age 78)
Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Comp: $145k
Dr. Neil Almstead Ph.D. (Age 57)
Chief Technical Operations Officer
Comp: $829.97k
Mr. Eric Pauwels (Age 63)
Chief Business Officer
Comp: $847.67k
Mr. Pierre Gravier M.S. (Age 38)
Chief Financial Officer
Ms. Christine Utter (Age 46)
Senior VP, Chief Accounting Officer & Head of People Services
Comp: $595.54k
Alex Kane
Investor Relations Officer
Mr. Mark Elliott Boulding (Age 63)
Executive VP & Chief Legal Officer
Comp: $824.09k
Ms. Jane Baj
Vice President of Corporate Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PTCT Stock Analysis - Frequently Asked Questions

Should I buy or sell PTC Therapeutics stock right now?: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 5 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" PTCT shares.
View PTCT analyst ratings or view top-rated stocks.
What is PTC Therapeutics' stock price target for 2024?: 13 brokers have issued 1-year price objectives for PTC Therapeutics' shares. Their PTCT share price targets range from $17.00 to $55.00. On average, they predict the company's stock price to reach $33.53 in the next year. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts.
How have PTCT shares performed in 2024?: PTC Therapeutics' stock was trading at $27.56 on January 1st, 2024. Since then, PTCT stock has decreased by 6.0% and is now trading at $25.92.
View the best growth stocks for 2024 here.
When is PTC Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our PTCT earnings forecast.
How can I listen to PTC Therapeutics' earnings call?: PTC Therapeutics will be holding an earnings conference call on Thursday, April 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were PTC Therapeutics' earnings last quarter?: PTC Therapeutics, Inc. (NASDAQ:PTCT) released its quarterly earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.29 by $0.53. The biopharmaceutical company had revenue of $307.06 million for the quarter, compared to the consensus estimate of $315.90 million.

What ETFs hold PTC Therapeutics' stock?: ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Morningstar US Small Growth (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Franklin Genomic Advancements ETF (HELX), Harbor Corporate Culture Small Cap ETF (HAPS), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC).
What guidance has PTC Therapeutics issued on next quarter's earnings?: PTC Therapeutics updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $600.0 million-$680.0 million, compared to the consensus revenue estimate of $612.3 million.
What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO?: 24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees.
What other stocks do shareholders of PTC Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD).
Who are PTC Therapeutics' major shareholders?: PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.01%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Lee Scott Golden, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey and Stuart Walter Peltz.
View institutional ownership trends.
How do I buy shares of PTC Therapeutics?: Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PTCT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PTC Therapeutics (PTCT) Stock Price, News & Analysis

PTC Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About PTC Therapeutics Stock (NASDAQ:PTCT)

PTCT Stock Price History

PTCT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PTCT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™